EP Patent

EP3826613B1 — Parenteral dosage form of carboplatin

Assigned to Sun Pharmaceutical Industries Ltd · Expires 2024-11-20 · 1y expired

What this patent protects

Patent listed against Paraplatin.

Drugs covered by this patent

Paraplatin (Carboplatin) · MYLAN SEIYAKU Ltd

Patent Metadata

Patent number: EP3826613B1
Jurisdiction: EP
Classification: —
Expires: 2024-11-20
Drug substance claim: No
Drug product claim: No
Assignee: Sun Pharmaceutical Industries Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.